Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

Lantern Pharma announced the successful completion of its Phase 1a clinical trial (NCT05933265) for LP-184, marking a key milestone in its AI drug development efforts. The trial met all primary endpoints with a favorable safety and pharmacokinetic profile plus early signs of antitumor activity.